Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor
activity in preclinical models of difficult-to-treat solid and liquid tumors without
imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered
orally once every week in combination with dexamethasone to patients with relapsed/refractory
multiple myeloma.
Funding Source - FDA OOPD